logo-loader
viewFeedback PLC

Feedback surges as TexRAD licensee StoneChecker receives green light from FDA

The medical imaging firm said it believed the StoneChecker software, now approved for sale in the US market, was using its TexRAD software

Feedback PLC - Feedback surges as TexRAD licensee StoneChecker receives green light from FDA
StoneChecker is used to assess kidney stones

Feedback PLC (LON:FDBK) shares surged on Friday after StoneChecker Software, a product of IQ-AI Limited (LON:IQAI) subsidiary Imaging Biometrics, received regulatory clearance by the US Food and Drug Administration (FDA).

READ: IQ-AI soars as StoneChecker software gets US FDA sign-off

StoneChecker, which is used to assess kidney stones, is a licensee of Feedback’s TexRAD software, however, the medical imaging firm it was currently not able to evaluate the level of income it would accrue as a result of the FDA clearance.

That didn’t stop the excitement from investors, as the shares jumped 16.3% to 1.3p in late-afternoon trading.

Quick facts: Feedback PLC

Price: 1.025 GBX

LSE:FDBK
Market: LSE
Market Cap: £5.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Feedback PLC named herein, including the promotion by the Company of Feedback PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Feedback PLC 'very close to standing up some pilots' for its Bleepa app

Feedback PLC's (LON:FDBK) Tom Oakley caught up with Proactive London's Andrew Scott following the recent NHS Expo where they were showcasing the new Bleepa app. ''We had a great time, it was fantastic to have the product validated by all sorts of people from within the NHS as well as...

on 17/10/19

2 min read